Ascendis Pharma: Strong Yorvipath Momentum, Pipeline Upside, and Raised DCF Assumptions Underpin Buy Rating and $260 Target

Bank of America Securities analyst Tazeen Ahmad has reiterated their bullish stance on ASND stock, giving a Buy rating today.

Tazeen Ahmad has given his Buy rating due to a combination of factors, including Ascendis Pharma’s strong commercial execution and ambitious growth outlook. Management reports robust momentum for Yorvipath, with rising prescription volumes, improving insurance coverage, and currently low penetration of the PTH market, all of which point to substantial headroom for revenue expansion by 2030.

Tazeen Ahmad’s rating is based on the additional upside from the pipeline, particularly confidence in TransCon CNP ahead of its upcoming U.S. PDUFA decision and a potential EU approval later in the year. She also highlights ongoing efforts to broaden Skytrofa’s opportunity through geographic and label expansion, as well as upward adjustments to long-term revenue assumptions in her DCF model, which support the $260 price objective and reinforce the Buy recommendation.

Ahmad covers the Healthcare sector, focusing on stocks such as Denali Therapeutics, Argenx Se, and Ascendis Pharma. According to TipRanks, Ahmad has an average return of 2.8% and a 54.96% success rate on recommended stocks.

In another report released today, Wedbush also maintained a Buy rating on the stock with a $273.00 price target.